NEWS
Morphocell Technologies appoints Janahan Arulmoli as Vice President of Product Engineering
Montreal, QC, October 22, 2025 – Morphocell Technologies, a leader in regenerative medicine and tissue engineering to restore organ function, is excited to announce the appointment of Janahan Arulmoli, Ph.D., as Vice President of Product Engineering. This strategic addition marks the creation of Morphocell’s new Product Engineering department, reinforcing the company’s commitment to innovation, scalability, and continued growth as it advances toward clinical translation.
​
Dr. Arulmoli brings over 15 years of engineering leadership spanning regenerative medicine, cell and gene therapy, and implantable combination devices. His experience unites advanced cell biology with product design and engineering, translating breakthrough science into clinically and commercially viable solutions.
Prior to joining Morphocell, Dr. Arulmoli held senior roles at Vertex Pharmaceuticals and ViaCyte, Inc., where he spearheaded the development of implantable and combination device systems for stem cell-based therapies, including first-in-human programs for Type 1 diabetes. His leadership contributed to more than 10 global regulatory submissions and clinical trials, bridging R&D, regulatory, quality, and manufacturing functions to accelerate next-generation therapeutic platforms.
“Janahan’s appointment marks an important milestone for Morphocell as we continue to expand our organization and strengthen our ability to deliver transformative therapies to patients,” said Dr. Massimiliano Paganelli, Chief Executive Officer of Morphocell Technologies. “His experience in bringing engineered cell therapy products from concept to clinic, combined with his technical acumen and collaborative leadership, will play a critical role as we scale our platform and prepare for the next phase of development. This is another step forward in Morphocell’s evolution as we grow, innovate, and continue to move boldly toward clinical and manufacturing excellence.”
​
Dr. Arulmoli holds a Ph.D. and M.S. in Biomedical Engineering from the University of California, Irvine, and a B.S. in Chemical Engineering from the University of California, San Diego. His expertise spans product and process engineering, regulatory strategy, and device development, with a focus on enabling scalable, integrated therapeutic solutions.
​​“I am thrilled to join Morphocell at such a pivotal moment in its growth,” said Dr. Arulmoli. “The company’s vision, combining breakthrough science, engineering precision, and patient-centered purpose, aligns perfectly with my passion for translating innovation into tangible impact. Together, we will continue building the technologies and systems that will define the future of regenerative medicine.”
​​
​This appointment highlights Morphocell Technologies’ ongoing momentum and strategic expansion, following key leadership additions across development, business, and governance over the past two years. Dr. Arulmoli’s arrival reinforces Morphocell’s focus on scientific excellence, operational scalability, and global readiness as it advances its regenerative platform toward the clinic.
​
About Morphocell Technologies:
Morphocell Technologies is a Montreal-based regenerative medicine company focused on the development and commercialization of stem cell-derived tissue and organ replacement therapies. Its iPSC-derived platform technology addresses severe organ deficiencies, beginning with liver disease, and holds broad potential across multiple therapeutic areas. Morphocell’s mission is to transform patient outcomes through scientific innovation, technical excellence, and continuous progress in the field of regenerative medicine.
Media Contact:
Zaynah Ibrahim
+ 1 (514) 373-6444 ext. 106